Sonnet chief medical officer, richard kenney, m.d., to present at the 6th annual cytokine-based drug development summit

Princeton, n.j., may 01, 2025 (globe newswire) -- sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company" or "sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (tme), today announced it will present at the 6 th annual cytokine-based drug development summit being held may 15-16, 2025 in boston, ma.
SONN Ratings Summary
SONN Quant Ranking